Spero Therapeutics Inc (NASDAQ:SPRO) Expected to Post Quarterly Sales of $1.38 Million

Wall Street brokerages predict that Spero Therapeutics Inc (NASDAQ:SPRO) will report $1.38 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Spero Therapeutics’ earnings, with the highest sales estimate coming in at $2.50 million and the lowest estimate coming in at $400,000.00. Spero Therapeutics reported sales of $660,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 109.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Spero Therapeutics will report full year sales of $18.17 million for the current financial year, with estimates ranging from $13.62 million to $25.92 million. For the next year, analysts anticipate that the business will post sales of $10.29 million, with estimates ranging from $10.00 million to $10.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. The business had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $6.95 million.

SPRO has been the topic of a number of research analyst reports. TheStreet downgraded Spero Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, July 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Spero Therapeutics in a report on Monday, August 12th. Zacks Investment Research downgraded Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Friday. Finally, ValuEngine raised Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $20.60.

Large investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new stake in shares of Spero Therapeutics in the second quarter worth about $25,000. Marshall Wace LLP acquired a new stake in shares of Spero Therapeutics in the first quarter worth about $39,000. D.A. Davidson & CO. acquired a new stake in shares of Spero Therapeutics in the second quarter worth about $115,000. Virtu Financial LLC acquired a new stake in shares of Spero Therapeutics in the first quarter worth about $134,000. Finally, Wells Fargo & Company MN lifted its position in shares of Spero Therapeutics by 187.9% in the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after buying an additional 8,915 shares during the last quarter. 45.08% of the stock is owned by institutional investors.

Shares of SPRO stock traded up $0.22 on Friday, reaching $10.00. 4,147 shares of the company’s stock traded hands, compared to its average volume of 30,021. Spero Therapeutics has a 12-month low of $5.52 and a 12-month high of $14.48. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.66 and a current ratio of 13.66. The company has a market capitalization of $182.50 million, a P/E ratio of -3.85 and a beta of 2.08. The business’s 50 day moving average price is $10.29 and its two-hundred day moving average price is $11.52.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Story: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.